& d pipelineadynovionzeald etirinotecan pegol amikacin inhale nktr 061 ciprofloxacin dry powder for inhalation dpi fovista nktr 181pegph20dapirolizumab pegol anti cd40l nktr 214nktr 358nktr 255nktr 119clinical trialsour medicinesu.s . medicines marketed by our partnerseu medicines marketed by our partnersinvestigational medicinesour scienceresearch platformscientific & clinical data presentationsscientific & medical eventsinvestorsabout uspress releasesinvestor eventsstock informationhistoric stock lookupanalyst coveragefinancials & filingssec filingsannuals and proxiesquarterly resultscorporate governanceinvestor contactse mails alertsmediamedia roomvideo galleryimage gallerycareersoverviewlife at nektarsearch jobsbenefits at nektarbenefits at san francisco californiabenefits at huntsville alabamabenefits at hyderabad indiainformation for recruiters new pathways to smarter medicinetm cutting edge chemistry . life changing biology.tm icon1 icon2 icon3 bringing hope to millions of patients by creating new medicines that treat serious medical needs . more improving human health through the power of a revolutionary chemistry platform . more developing groundbreaking therapies by unleashing the true potential of critical biological pathways . more events sep 27 nektar therapeutics conference call to discuss announcement of new clinical collaboration with bristol myers squibb 9 00 a.m. et 6 00 a.m. pt webcast link http edge.media server.com m p tm76xtyh jun 08 jefferies 2016 healthcare conference new york ny presentation 11 30 a.m. et 8 30 a.m. pt event will be webcastpresentation slides leadership spotlight dr. jonathan zalevsky vp biology discusses nktr 214 watch latest news sep 27 nektar therapeutics to host investor & analyst conference call to discuss new clinical collaboration with bristol myers squibb sep 27 bristol myers squibb and nektar therapeutics announce oncology clinical collaboration to evaluate the combination of opdivo nivolumab and nktr 214 our pipeline we are focused on using new chemistry approaches to make better medicines to treat cancer chronic pain and auto immune disease . nktr 214 immuno oncology phase 1 2 nktr 181 chronic pain phase 3 onzeald etirinotecan pegol oncology phase 3 99 million patients benefit from our medicines 1212 approved products around the world 1010 new medicines in development pipeline cutting edge facilities dynamic teams impactful work our culture we are supported by a dynamic team rich in scientific business and medical expertise across three locations . read more quick links our company our pipeline our medicines our science investors media careers contact privacy terms of use connect locationssan francisco ca huntsville al hyderabad india copyright nektar 2016